Literature DB >> 33718270

T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression.

Francisco Javier Gil-Etayo1, Patricia Suàrez-Fernández2, Oscar Cabrera-Marante1, Daniel Arroyo1, Sara Garcinuño2, Laura Naranjo1, Daniel E Pleguezuelo1, Luis M Allende1,2, Esther Mancebo1,2, Antonio Lalueza2,3,4, Raquel Díaz-Simón3, Estela Paz-Artal1,2,5, Antonio Serrano1,2,6.   

Abstract

The immune response type organized against viral infection is determinant in the prognosis of some infections. This work has aimed to study Th polarization in acute COVID-19 and its possible association with the outcome through an observational prospective study. Fifty-eight COVID-19 patients were recruited in the Medicine Department of the hospital "12 de Octubre," 55 patients remaining after losses to follow-up. Four groups were established according to maximum degree of disease progression. T-helper cell percentages and phenotypes, analyzed by flow cytometer, and serum cytokines levels, analyzed by Luminex, were evaluated when the microbiological diagnosis (acute phase) of the disease was obtained. Our study found a significant reduction of %Th1 and %Th17 cells with higher activated %Th2 cells in the COVID-19 patients compared with reference population. A higher percent of senescent Th2 cells was found in the patients who died than in those who survived. Senescent Th2 cell percentage was an independent risk factor for death (OR: 13.88) accompanied by the numbers of total lymphocytes (OR: 0.15) with an AUC of 0.879. COVID-19 patients showed a profile of pro-inflammatory serum cytokines compared to controls, with higher levels of IL-2, IL-6, IL-15, and IP-10. IL-10 and IL-13 were also elevated in patients compared to controls. Patients who did not survive presented significantly higher levels of IL-15 than those who recovered. No significant differences were observed according to disease progression groups. The study has shown that increased levels of IL-15 and a high Th2 response are associated with a fatal outcome of the disease.
Copyright © 2021 Gil-Etayo, Suàrez-Fernández, Cabrera-Marante, Arroyo, Garcinuño, Naranjo, Pleguezuelo, Allende, Mancebo, Lalueza, Díaz-Simón, Paz-Artal and Serrano.

Entities:  

Keywords:  COVID-19; SARS-Cov2; T-helper; cytokines; immunity

Mesh:

Substances:

Year:  2021        PMID: 33718270      PMCID: PMC7952877          DOI: 10.3389/fcimb.2021.624483

Source DB:  PubMed          Journal:  Front Cell Infect Microbiol        ISSN: 2235-2988            Impact factor:   5.293


  80 in total

Review 1.  Molecules associated with human Th1 or Th2 cells.

Authors:  F Annunziato; G Galli; L Cosmi; P Romagnani; R Manetti; E Maggi; S Romagnani
Journal:  Eur Cytokine Netw       Date:  1998-09       Impact factor: 2.737

Review 2.  Comprehensive Phenotyping of T Cells Using Flow Cytometry.

Authors:  Charlotte M Mousset; Willemijn Hobo; Rob Woestenenk; Frank Preijers; Harry Dolstra; Anniek B van der Waart
Journal:  Cytometry A       Date:  2019-02-04       Impact factor: 4.355

3.  Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis.

Authors:  Raymond S M Wong; Alan Wu; K F To; Nelson Lee; Christopher W K Lam; C K Wong; Paul K S Chan; Margaret H L Ng; L M Yu; David S Hui; John S Tam; Gregory Cheng; Joseph J Y Sung
Journal:  BMJ       Date:  2003-06-21

4.  Signals of Th2 immune response from COVID-19 patients requiring intensive care.

Authors:  Luca Roncati; Vincenzo Nasillo; Beatrice Lusenti; Giovanni Riva
Journal:  Ann Hematol       Date:  2020-05-08       Impact factor: 3.673

Review 5.  The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.

Authors:  Yan-Rong Guo; Qing-Dong Cao; Zhong-Si Hong; Yuan-Yang Tan; Shou-Deng Chen; Hong-Jun Jin; Kai-Sen Tan; De-Yun Wang; Yan Yan
Journal:  Mil Med Res       Date:  2020-03-13

6.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

7.  T cell responses to whole SARS coronavirus in humans.

Authors:  Chris Ka-fai Li; Hao Wu; Huiping Yan; Shiwu Ma; Lili Wang; Mingxia Zhang; Xiaoping Tang; Nigel J Temperton; Robin A Weiss; Jason M Brenchley; Daniel C Douek; Juthathip Mongkolsapaya; Bac-Hai Tran; Chen-lung Steve Lin; Gavin R Screaton; Jin-lin Hou; Andrew J McMichael; Xiao-Ning Xu
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

Review 8.  Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression.

Authors:  Mary Kathryn Bohn; Alexandra Hall; Lusia Sepiashvili; Benjamin Jung; Shannon Steele; Khosrow Adeli
Journal:  Physiology (Bethesda)       Date:  2020-09-01

9.  A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

Authors:  Bin Cao; Yeming Wang; Danning Wen; Wen Liu; Jingli Wang; Guohui Fan; Lianguo Ruan; Bin Song; Yanping Cai; Ming Wei; Xingwang Li; Jiaan Xia; Nanshan Chen; Jie Xiang; Ting Yu; Tao Bai; Xuelei Xie; Li Zhang; Caihong Li; Ye Yuan; Hua Chen; Huadong Li; Hanping Huang; Shengjing Tu; Fengyun Gong; Ying Liu; Yuan Wei; Chongya Dong; Fei Zhou; Xiaoying Gu; Jiuyang Xu; Zhibo Liu; Yi Zhang; Hui Li; Lianhan Shang; Ke Wang; Kunxia Li; Xia Zhou; Xuan Dong; Zhaohui Qu; Sixia Lu; Xujuan Hu; Shunan Ruan; Shanshan Luo; Jing Wu; Lu Peng; Fang Cheng; Lihong Pan; Jun Zou; Chunmin Jia; Juan Wang; Xia Liu; Shuzhen Wang; Xudong Wu; Qin Ge; Jing He; Haiyan Zhan; Fang Qiu; Li Guo; Chaolin Huang; Thomas Jaki; Frederick G Hayden; Peter W Horby; Dingyu Zhang; Chen Wang
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

10.  Functional exhaustion of antiviral lymphocytes in COVID-19 patients.

Authors:  Meijuan Zheng; Yong Gao; Gang Wang; Guobin Song; Siyu Liu; Dandan Sun; Yuanhong Xu; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2020-03-19       Impact factor: 11.530

View more
  39 in total

Review 1.  Efficacy and safety of corticosteroid regimens for the treatment of hospitalized COVID-19 patients: a meta-analysis.

Authors:  Fangwen Zhou; Jiawen Deng; Kiyan Heybati; Qi Kang Zuo; Saif Ali; Wenteng Hou; Chi Yi Wong; Harikrishnaa Ba Ramaraju; Oswin Chang; Thanansayan Dhivagaran; Zachary Silver
Journal:  Future Virol       Date:  2022-06-03       Impact factor: 3.015

Review 2.  Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors.

Authors:  Roberta Rovito; Matteo Augello; Assaf Ben-Haim; Valeria Bono; Antonella d'Arminio Monforte; Giulia Marchetti
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

3.  Anti-ACTH antibodies in critically ill Covid-19 patients: A potential immune evasion mechanism of SARS-CoV-2.

Authors:  D Pérez-Torres; C Díaz-Rodríguez; A Armentia-Medina
Journal:  Med Intensiva (Engl Ed)       Date:  2022-08

Review 4.  Th17 Cells in Viral Infections-Friend or Foe?

Authors:  Iury Amancio Paiva; Jéssica Badolato-Corrêa; Débora Familiar-Macedo; Luzia Maria de-Oliveira-Pinto
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

5.  Different T cell related immunological profiles in COVID-19 patients compared to healthy controls.

Authors:  Armin Mahmoud Salehi Khesht; Vahid Karpisheh; Balsam Qubais Saeed; Angelina Olegovna Zekiy; Lis M Yapanto; Mohsen Nabi Afjadi; Mohsen Aksoun; Maryam Nasr Esfahani; Fatemeh Aghakhani; Mahsa Movahed; Navneet Joshi; Kazem Abbaszadeh-Goudarzi; Shahin Hallaj; Majid Ahmadi; Sanam Dolati; Ata Mahmoodpoor; Vida Hashemi; Farhad Jadidi-Niaragh
Journal:  Int Immunopharmacol       Date:  2021-05-28       Impact factor: 5.714

Review 6.  Infection and Immune Memory: Variables in Robust Protection by Vaccines Against SARS-CoV-2.

Authors:  Pankaj Ahluwalia; Kumar Vaibhav; Meenakshi Ahluwalia; Ashis K Mondal; Nikhil Sahajpal; Amyn M Rojiani; Ravindra Kolhe
Journal:  Front Immunol       Date:  2021-05-11       Impact factor: 7.561

Review 7.  Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.

Authors:  Patricia K Coyle; Anne Gocke; Megan Vignos; Scott D Newsome
Journal:  Adv Ther       Date:  2021-06-01       Impact factor: 3.845

8.  Landscape and selection of vaccine epitopes in SARS-CoV-2.

Authors:  Christof C Smith; Kelly S Olsen; Benjamin G Vincent; Alex Rubinsteyn; Kaylee M Gentry; Maria Sambade; Wolfgang Beck; Jason Garness; Sarah Entwistle; Caryn Willis; Steven Vensko; Allison Woods; Misha Fini; Brandon Carpenter; Eric Routh; Julia Kodysh; Timothy O'Donnell; Carsten Haber; Kirsten Heiss; Volker Stadler; Erik Garrison; Adam M Sandor; Jenny P Y Ting; Jared Weiss; Krzysztof Krajewski; Oliver C Grant; Robert J Woods; Mark Heise
Journal:  Genome Med       Date:  2021-06-14       Impact factor: 15.266

Review 9.  Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic.

Authors:  Samir Andrade Mendonça; Reka Lorincz; Paul Boucher; David T Curiel
Journal:  NPJ Vaccines       Date:  2021-08-05       Impact factor: 7.344

Review 10.  The Many Faces of JAKs and STATs Within the COVID-19 Storm.

Authors:  Alice H Grant; Armando Estrada; Yoshira M Ayala-Marin; America Y Alvidrez-Camacho; Georgialina Rodriguez; Elisa Robles-Escajeda; Denisse A Cadena-Medina; Alejandro C Rodriguez; Robert A Kirken
Journal:  Front Immunol       Date:  2021-07-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.